Luckschander Nicole, Allenspach Karin, Hall Jean, Seibold Frank, Gröne Andrea, Doherr Marcus G, Gaschen Frédéric
Department of Clinical Veterinary Medicine, Faculty of Veterinary Medicine, University of Bern, Switzerland.
J Vet Intern Med. 2006 Mar-Apr;20(2):221-7. doi: 10.1892/0891-6640(2006)20[221:pacaar]2.0.co;2.
The goal of this study was to investigate the correlation between perinuclear antineutrophilic cytoplasmic antibody (pANCA) and clinical scores before and after treatment in diarrheic dogs with food-responsive disease (FRD) or inflammatory bowel disease (IBD). pANCA serology was evaluated prospectively by indirect immunofluorescence in 65 dogs with signs of gastrointestinal disease, and if positive, pANCA antibody titers were determined. Thirty-nine dogs with FRD responded to a novel diet, and 26 dogs with IBD were treated with corticosteroids. The severity of clinical signs was scored by means of a canine IBD activity index (CIBDAI). At initial examination, a significantly (P = .002) higher percentage of dogs were pANCA-positive in the FRD group (62%) compared with the IBD group (23%). pANCA titers were significantly higher (P = .003) before treatment in the FRD group (median titer 100) compared with the IBD group (median titer 1). However, there was no difference in pANCA titers between the groups after respective treatments because dogs in the IBD group had a significant increase in pANCA titer after treatment. The CIBDAI score decreased significantly (P < .001) after treatment in both groups (74% moderate to severe in FRD dogs before versus 8% after treatment; 85% moderate to severe in IBD dogs before versus 32% after treatment). There was no correlation between pANCA status in FRD or IBD dogs before treatment and scores for CIBDAI, endoscopy, or histopathology before or after treatment, except for the endoscopic duodenal score in dogs with FRD after treatment (P = .03). A positive pANCA test before therapy may aid in the diagnosis of FRD.
本研究的目的是调查核周抗中性粒细胞胞浆抗体（pANCA）与食物反应性疾病（FRD）或炎症性肠病（IBD）腹泻犬治疗前后临床评分之间的相关性。对65只出现胃肠道疾病症状的犬进行前瞻性间接免疫荧光法评估pANCA血清学，若为阳性，则测定pANCA抗体滴度。39只FRD犬对新饮食有反应，26只IBD犬接受了皮质类固醇治疗。通过犬IBD活动指数（CIBDAI）对临床症状的严重程度进行评分。在初次检查时，FRD组（62%）pANCA阳性犬的百分比显著高于IBD组（23%）（P = 0.002）。与IBD组（中位数滴度1）相比，FRD组治疗前pANCA滴度显著更高（P = 0.003）（中位数滴度100）。然而，各组在各自治疗后pANCA滴度没有差异，因为IBD组犬治疗后pANCA滴度显著升高。两组治疗后CIBDAI评分均显著降低（P < 0.001）（FRD犬治疗前74%为中度至重度，治疗后为8%；IBD犬治疗前85%为中度至重度，治疗后为32%）。除了FRD犬治疗后的内镜十二指肠评分（P = 0.03）外，FRD或IBD犬治疗前的pANCA状态与治疗前后的CIBDAI、内镜检查或组织病理学评分之间均无相关性。治疗前pANCA检测呈阳性可能有助于FRD的诊断。
